Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 19

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 19
---
 you   
 that we will successfully develop any products, or if we do, that they will be commercially successful.                               |
| ● | Even if our product                                                                                                                   
 candidates receive marketing authorization from the FDA, and if the FDA does not find the manufacturing facilities of our future      
 contract manufacturers acceptable for commercial production, we still may not be able to commercialize any of our product candidates. |

Risks Relating to the Company’s Intellectual Property

| ● | Our                                                                                          
 pending patent applications may not result in issued patents, and any patents that may be    
 granted could include only limited claims. As a result, our intellectual property protection 
 may be weaker than anticipated, which could make it more difficult for us to establish or    
 maintain a competitive position.                                                             |

| ● | Our                                                                                             
 inability to protect our trademarks, patents and trade secrets may prevent us from successfully 
 marketing our products and competing effectively.                                               |

| ● | The                                                                                          
 patenting process, enforcement of issued patents, and defense against claims of infringement 
 are inherently risky.                                                                        |

| ● | We                                                                                              
 may be unable to secure new patent protection for our LPLT-based immunization platform approach 
 through additional patent applications, or may receive only partial claim approvals, which      
 could limit the scope of intellectual property protection.                                      |

| ● | We                                                                                       
 may be subject to legal claims against us or claims by us which could have a significant 
 impact on our resulting financial performance.                                           |

<div align='center'>6</div>

Risks Related to Operations in Israel

| ● | Our principal executive                                                                                                              
 offices, most of our research and development activities and other significant operations are located in Israel, and, therefore,     
 our results may be adversely affected by political, economic and military instability in Israel, including Israel’s multi-front      
 war with terrorist groups in neigh boring countries, such as Hezbollah in Lebanon and Hamas in the Gaza Strip, and state actors such 
 as Iran, and Israel’s response thereto.                                                                                              |

| ● | Our operations and the operations may be disrupted as a result of the obligation of Israeli citizens to perform military service. |

| ● | Our future sales may be adversely affected 
 by boycotts of Israel.                     |
| ● | There may be limitations                   
 on transfers of our technology.            |

Risks Related to Our Common Stock

| ● | Our principal stockholders                                                                                                               
 can significantly influence or control matters requiring a shareholder vote and other stockholders may not have the ability to influence 
 corporate transactions. The